Jared Holz

Healthcare Equity Strategist, Mizuho
· tracked since Jan 2026
Calls 1 2 Posts tracked · 0.0/day
Calls
7d 0
30d 0
90d 0
Best Calls
No live winners yet
Worst Calls
NVO long -13.8%
Most Mentioned
NVO ×1
Recent Calls
NVO long 3 months ago
Win Rate 0% Long 1 Short 0
Win Rate
7d 100%
30d 0%
90d 0%
Average Return -13.8% Long Return -13.8% Short Return -
Average Return
7d +1.0%
30d -22.1%
90d -3.6%
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
Opened
Entry
P&L
Thesis
Theme
Source
NVO Novo Nordisk A/S Novo Nordisk A/S
Long
Feb 11
$48.74
-13.8%
Holz highlights that NVO shares are back at 2024 lows while LLY has outperformed, despite both having similar duopoly status in the obesity market. The valuation gap has become "alarming." NVO's new pill (Wegovy oral) has 15x better uptake than the injection launch, and they are aggressively suing compounders (HIMS) to protect their moat. LONG NVO / SHORT LLY. Expect mean reversion as NVO resolves supply issues and flexes legal power. LLY's oral candidate could outperform; compounding pharmacies might win legal battles.
Holz highlights that NVO shares are back at 2024 lows while LLY has outperformed, despite both having similar duopoly status in the obesity market. The valuation gap has become "alarming." NVO's new pill (Wegovy oral) has 15x better uptake than the injection launch, and they are aggressively suing compounders (HIMS) to protect their moat. LONG NVO / SHORT LLY. Expect mean reversion as NVO resolves supply issues and flexes legal power. LLY's oral candidate could outperform; compounding pharmacies might win legal battles.
Healthcare
YOUTUBE
Showing 1 of 1 picks ยท sorted by mentions